CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42 enrolled
Drug / intervention
Ergocalciferol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00957879
NCT00957879N/ACompleted
CompareCT.gov

Effect of Different Vitamin D Preparations on Circulating FGF23 Levels in Vitamin D Deficient Caucasian and African-American Men and Women

Massachusetts General Hospital·interventional·Posted Aug 13, 2009·Updated Apr 19, 2012

In Brief

A clinical study evaluating Ergocalciferol and Calcitriol for Vitamin D Deficiency. Completed, enrolled 42 participants across 1 site.

Detailed Summary

Fibroblast growth factor 23 (FGF23) is a new hormone which controls phosphate and vitamin D levels in humans. Excess FGF23 is associated with an increased risk of death in patients with chronic kidney disease. In this study the investigators are investigating the effects of different forms of vitamin D on FGF23 levels in the blood in order to increase our understanding of how this important hormone works.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitamin D Deficiency
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2009
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.9 years ago

Interventions

Ergocalciferoldietary

Ergocalciferol 50000 international units by mouth weekly for 12 weeks

Calcitrioldietary

Calcitriol 0.5 mcg by mouth daily for 12 weeks